Teva wins FDA approval for IGALMI as first at-home treatment for agitation in adults with schizophrenia or bipolar disorder
TEVA•
TEVA•Teva received FDA approval for IGALMI as the first at-home treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. Phase 3 SERENITY results met the primary safety and tolerability endpoint, with no treatment discontinuations due to tolerability.
Teva received FDA approval for IGALMI as an at-home treatment for agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. The company said it is the first at-home treatment for this use.
Phase 3 SERENITY results met the primary safety and tolerability endpoint, with no treatment discontinuations due to tolerability. Tolerability remained consistent with repeat dosing during the 12-week study. Teva acquired IGALMI in late October 2026 and said it will announce commercialization plans for at-home use later.